In the context of CML, we believe that one reasonable approach would be to examine the effects of these drugs alone and in combination with BCR::ABL1 TKI in TKI‐resistant non‐transplantable patients or in patients who have drug‐resistant CML BP. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.